MassGen Nederlands Hersentumorcentrum Amsterdam copy

Tannous copyIsabel Arrillaga Romany headshot Mathilde Kouwenhoven copy

Principle Investigators: Dr. Bakhos Tannous, Dr. Isabel Arrillaga-Romany, Dr. Mathilde Kouwenhoven, Dr. Myra van Linde (not pictured)

Disease: Glioblastoma

Research Description: Glioblastomas (GBMs) are the most common and most lethal form of brain cancers in adults. Length of survival following diagnosis is typically 12-15 months, and less than 10% of patients survive beyond 5 years. The standard chemotherapy for GBM is temozolomide (TMZ), but only about half of patients treated with TMZ respond. Dr. Tannous has shown that a combination of TMZ and another generic drug, hydroxyurea, can increase GBM survival rates in mice. He and his collaborator in the Netherlands, Dr. Kouwenhoven, now propose a clinical trial to test this novel combination in humans. This pilot trial seeks to determine the best dose of TMZ/hydroxyurea and will determine the impact of the combination treatment on survival. If successful, results from this clinical trial could lead to a new therapy option for patients suffering from GBM.

CWR Funding Role: Participating funder

CWR Funding Partner: Goldman Philanthropic Partnerships and Anonymous

CWR Funding Start Date: October 2018

Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*

*required

If the link above doesn't work, please email susan@cureswithinreach.org with your Full Name and Email Address to sign up!

 

Cures Within Reach

134 N. LaSalle, #1130
Chicago, IL 60602

info@cureswithinreach.org

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes. 

Partnership for Cures DBA Cures Within Reach is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.

 

Sunday the 21st. Copyright 2018 Cures Within Reach.